Ketamine vs Electroconvulsive Therapy for Treatment-Resistant Depression: A Secondary Analysis of a Randomized Clinical Trial

Ketamine vs Electroconvulsive Therapy for Treatment-Resistant Depression: A Secondary Analysis of a Randomized Clinical Trial

ABSTRACT

The ELEKT-D trial demonstrated that intravenous ketamine was noninferior to ECT for nonpsychotic TRD. This secondary analysis aimed to identify clinical features guiding the selection of ketamine vs ECT.

MAIN OUTCOMES AND MEASURES

The study found that outpatients with moderately severe or severe depression may consider ketamine over ECT for TRD, as they showed greater improvement with ketamine treatment.

CONCLUSIONS AND RELEVANCE

These findings suggest that intravenous ketamine may be a preferable option for certain patient groups with TRD, based on the observed greater improvement in depression among outpatients with nonpsychotic TRD who had moderately severe or severe depression. This could inform shared decision-making for patients with TRD.

PMID:38916891 | DOI:10.1001/jamanetworkopen.2024.17786

Clinical trials are key to developing safe and effective treatments. It’s important to extend their benefits into everyday medical practice. DocSym, our AI-driven platform, helps by consolidating ICD-11 standards, clinical protocols, and research into a single, easily accessible knowledge base for clinicians.

In today’s healthcare environment, streamlining operations is crucial. Our mobile apps support scheduling, monitoring treatments, and telemedicine, making it easier to manage patient care and expand services digitally.

By using AI, clinics can enhance their workflows and improve patient outcomes, reduce paper routine. Learn more about how we can help at aidevmd.com.